Thank you very much, Mr. Chair. I have one quick question and then I will yield the rest of my time to Madam Demers, who has spent a great deal of time on this issue. I know she's very passionate about this and I want to give her an ample amount of time to ask her questions.
First of all, thank you to the witnesses for appearing today.
My comment is, at least we have a decision. My frustration the last time this issue came before this committee was the fact that there really was no decision. We seemed to be in limbo.
I wonder if there could be some consideration given to developing some literature for patient education that could be distributed to family physicians nationwide. We talked in our study of childhood obesity about how GPs could be given information for their patients. The same thing could apply here.
Perhaps there could be a piece of literature put together that GPs could distribute to their patients, because the number of Canadian women who will actually see a label and read through all of the information will reflect a very low percentage. I think if we make it easier for Canadian physicians to pass on this scientific-based, non-biased information to their patients, then it would help Canadian women make that decision. I do think this is significantly different from the aspirin example. There's significant post-surveillance requirements here, much more so than any other device or drug that I'm aware of.
Since it's been studied for four years, I think it's a reasonable request. I wonder if you'd give it some consideration and take that back to Health Canada.
That's my question. The rest of my time will go to Madam Demers following the response.
Thank you, Mr. Chair.